Interobserver variability remains for TBS I, II, and III-other despite group review. The implementation of the two-tiered AUS will simplify our clinical practice and is expected to decrease interobserver variability in the use of AUS-nuclear atypia, which has a higher risk of malignancy.
Chen‐Yost et al. (Sun,) studied this question.